Noticias de ELVN_US

Mercado

Noticias del mercado

Últimas noticias sobre ELVN_US — 82 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ELVN_US ✕ 82 resultados
02/10/2026 ELVN_US — Benzinga
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Frida
02/10/2026 ELVN_US — MarketScreener
Morgan Stanley Initiates Enliven Therapeutics at Overweight
02/10/2026 ELVN_US — Investing.com
Morgan Stanley initiates Enliven Therapeutics stock at overweight By Investing.com
02/10/2026 ELVN_US — Investing.com
Morgan Stanley initiates Enliven Therapeutics stock at overweight
02/10/2026 ELVN_US — Benzinga
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
01/10/2026 ELVN_US — GuruFocus
ELVN Initiated Coverage by JP Morgan -- Rating Set to Overweight
01/10/2026 ELVN_US — MarketScreener
JPMorgan Initiates Enliven Therapeutics at Overweight With $75 Price Target
01/10/2026 ELVN_US — Investing.com
Enliven Therapeutics stock initiated at Overweight by JPMorgan
01/10/2026 ELVN_US — Stock Traders Daily
Understanding the Setup: (ELVN) and Scalable Risk

Price-action only: Enliven Therapeutics Inc. (ELVN) movements set the tone for institutional models. Understanding the Setup: (ELVN) and Scalable Risk

01/10/2026 ELVN_US — Investing.com
Enliven Therapeutics stock initiated at Overweight by JPMorgan
01/10/2026 ELVN_US — Stock Titan
Director Jeffrey Garland proposes selling 13,000 Enliven Therapeutics (NASDAQ: ELVN) shares.
22/09/2026 ELVN_US — Investing.com
Enliven Therapeutics CMO Helen Collins sells $251k in shares By Investing.com
22/09/2026 ELVN_US — Investing.com
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com
22/09/2026 ELVN_US — Investing.com
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock
22/09/2026 ELVN_US — Investing.com
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com
22/09/2026 ELVN_US — Investing.com
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com
21/09/2026 ELVN_US — MarketScreener
Enliven Therapeutics Insider Sold Shares Worth $251,754, According to a Recent SEC Filing
21/09/2026 ELVN_US — Stock Titan
Enliven Therapeutics (ELVN) CFO exercises options, sells 6,018 shares

El director financiero Benjamin Hohl ejerció 3.982 opciones a 14,85 dólares y vendió 6.018 acciones a entre 50 y 51,49 dólares el 17 de septiembre de 2026 según un plan de la Regla 10b5-1, quedando 181.018 opciones.

21/09/2026 ELVN_US — Simply Wall Street
Enliven Therapeutics (Nasdaq:ELVN) - Stock Analysis
18/09/2026 ELVN_US — DirectorsTalk Interviews
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotech Innovator with a 47% Upside Potential

Página 3 de 5